ARA-290 vs Cortagen

Non-hematopoietic EPO analogue; activates innate repair receptor (IRR/EPOR/CD131 complex) without erythropoietic effects; promotes tissue repair and nerve healing

ARA 290 (cibinetide) is a synthetic 11-amino-acid peptide derived from the helix B region of erythropoietin (EPO), engineered to activate the innate repair receptor (IRR) — a tissue-protective heteroreceptor complex comprising the EPO receptor and the β-common receptor (CD131) — without engaging the classical erythropoietic EpoR homodimer, thereby separating EPO's tissue-protective signaling from its hematopoietic effects. By selectively engaging the IRR rather than the erythropoietic receptor, cibinetide activates anti-inflammatory and anti-apoptotic intracellular pathways in neurons, endothelium, and other metabolically active tissues without causing erythrocytosis, hypertension, or thrombosis, making it a candidate for neuropathy and inflammatory tissue injury contexts. Randomized, double-blind Phase 2 clinical trials have demonstrated that cibinetide improves metabolic control and neuropathic symptom scores in patients with type 2 diabetes, and a separate study demonstrated improved corneal nerve fiber abundance in patients with sarcoidosis-associated small fiber neuropathy — providing human proof-of-concept for both diabetic and inflammatory peripheral neuropathy applications. Cibinetide (ARA 290) is an investigational compound that has not received FDA approval for any indication; Phase 2 data supports further investigation in peripheral neuropathies, but no Phase 3 completion or regulatory filing has occurred as of 2025.

Brain cortex-derived tetrapeptide that modulates gene expression in neural and cardiac tissue through chromatin regulatory mechanisms; microarray analysis demonstrates broad transcriptional effects following administration.

Cortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Pro) classified as a Khavinson-class bioregulator derived from cerebral cortex tissue, investigated for gene expression regulatory effects in neural and cardiac tissue. As a Khavinson-class bioregulator, cortagen is proposed to modulate transcriptional activity in aging target tissue by interacting with gene regulatory elements; microarray analysis of cardiac gene expression following cortagen administration has demonstrated broad effects on transcriptional profiles across multiple functional gene categories, suggesting tissue-regulatory activity beyond its cortical tissue origin. Published research on Khavinson-class peptides has further characterized the systematic gene expression regulatory potential of short bioregulator peptides across tissue types, providing the mechanistic context within which cortagen's transcriptional effects are interpreted. Cortagen has no FDA approval or regulatory approval in any major Western jurisdiction; evidence derives from Khavinson-series preclinical studies with no independent clinical trials published in Western-indexed journals. Cortagen benefits investigated in preclinical research include neuroprotective effects in neural tissue, cardiovascular gene expression modulation, and support for vascular wall integrity in aged animal models. As a brain cortex-derived Khavinson bioregulator, cortagen is proposed to regulate transcription in neural and cardiac tissue through chromatin-level mechanisms, potentially preserving tissue-specific gene expression patterns that decline with aging. Research interest encompasses cortagen's role in neurological aging, post-ischemic brain tissue recovery in preclinical models, and combined bioregulator protocols that pair cortagen with cardiovascular and metabolic peptides for comprehensive longevity applications. Cortagen is a research compound with no regulatory approval in any jurisdiction; evidence is limited to preclinical studies and Russian clinical research literature, with no independent randomized trials published in Western peer-reviewed journals.